Mature results from the 61.2 Gy concomitant boost thoracic radiotherapy arm (stopped after interim analysis) of CALGB 30610/RTOG 0538 in 93 patients with limited-stage SCLC: median overall survival 32.3 months, 5-year survival 28.5%; grade 3 non-haematological AEs 40.9%.
RCTn = 93
Bogart et al. Mature Outcomes of 61.2 Gy Concomitant Boost Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538